Epelsiban clinical trials
Also written GSK557296.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses epelsiban is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses epelsiban is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women VolunteersCompletedPhase 1GlaxoSmithKlineNCT02703181Written as Epelsiban (GSK557296)
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female VolunteersCompletedPhase 1GlaxoSmithKlineNCT02257359Written as Epelsiban
- A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature EjaculationCompletedPhase 2GlaxoSmithKlineNCT01021553Written as GSK557296
- Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat DosingCompletedPhase 1GlaxoSmithKlineNCT01669083Written as GSK557296 10 mg
- A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of EpelsibanTerminatedPhase 1GlaxoSmithKlineNCT02213029Written as Epelsiban
- Placebo-controlled Proof of Concept Study of Epelsiban in Women With AdenomyosisWithdrawnPhase 2GlaxoSmithKlineNCT02794467Written as Epelsiban
- A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.CompletedPhase 1GlaxoSmithKlineNCT00549211Written as GSK557296
Codes
What other systems call epelsiban · ClinicalTrials.gg INT006023
- MeSH (NLM) C571185epelsibanOne source NLM
- UNII (FDA) T2EZ19HX73EPELSIBANConfirmed FDA, NLM, Wikidata
- Wikidata Q5382095epelsibanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99151EpelsibanOne source FDA
- DrugBank DB11934One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571185 | epelsiban | One source NLM |
| UNII (FDA) | T2EZ19HX73 | EPELSIBAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5382095 | epelsiban | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99151 | Epelsiban | One source FDA |
| DrugBank | DB11934 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.